

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)**U.S. PATENT APPLICATION PUBLICATIONS**[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)**FOREIGN PATENT DOCUMENTS**[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
								<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)**NON-PATENT LITERATURE DOCUMENTS**[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

/J.H./	1	BOISSIER, S. et al., Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices, Cancer Res, 1997, 3890-3894, 57(18).	<input type="checkbox"/>
	2	FOURNIER, P. et al., Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats, Cancer Res, 2002, 6538-6544, 62(22).	<input type="checkbox"/>
	3	FROMIGUE, O. et al., Bisphosphonates induce breast cancer cell death in vitro, J Bone Miner Res, 2000, 2211-2221, 15(11).	<input type="checkbox"/>
	4	HIRAGA, T. et al., The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases, Cancer Res, 2001, 4418-4424, 61(11).	<input type="checkbox"/>
	5	JAGDEV S.P. et al., The bisphosphonate, zoledronic acid, induces aptosis of breast cancer cells: evidence of synergy with paclitaxel, Br J Cancer, 2001, 1126-1134, 84(8).	<input type="checkbox"/>
	6	PADALECKI, S.S. et al., Actions of bisphosphonates in animal models of breast cancer, Breast Cancer Res, 2002, 35-41, 4(1).	<input type="checkbox"/>
	7	VAN DER PLUIJM, G. et al., Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro, J Clin Invest, 1996, 698-705, 98(3).	<input type="checkbox"/>
	8	STEARNS, ME et al., Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice, Clin Exp Metastasis, 1998; 693-702; 16(8).	<input type="checkbox"/>
	9	VIRTANEN, S. S. et al, Alendronate Inhibits Invasion of PC-3 Prostate Cancer Cells by Affecting the Mevalonate Pathway, Cancer Res, 2002, 2708-2714, 62(9).	<input type="checkbox"/>
/J.H./	10	YONEDA, T. et al., Actions of Bisphosphonate on Bone Metastasis in Animal Models of Breast Carcinoma, Cancer (Supplement), 2000, 2979-2988, 88(12).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

EXAMINER SIGNATURE

Examiner Signature	/Julie Ha/	Date Considered	12/04/2008
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.